Info: Read More
    		•
  • 中药标准品生产商，产品定制服务
    		•
  • 首页
  • 天然产物
  • 产品文献
  • 最新产品
  • 订购流程
  • 公司新闻
  • 公司简介
  • 联系我们
  • 首页
  • /
  • 天然产物（标准品）
  • /
  • 盐酸普拉克索

    • 盐酸普拉克索

    Pramipexole dihydrochloride

    盐酸普拉克索
    		产品编号 CFN90019
    CAS编号 104632-25-9
    分子式 = 分子量 C10H19Cl2N3S = 284.25
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Alkaloids
    植物来源
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    盐酸普拉克索 CFN90019 104632-25-9 1mg QQ客服：1413575084
    盐酸普拉克索 CFN90019 104632-25-9 5mg QQ客服：1413575084
    盐酸普拉克索 CFN90019 104632-25-9 10mg QQ客服：1413575084
    盐酸普拉克索 CFN90019 104632-25-9 20mg QQ客服：1413575084
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

    2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。 但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常，这些可用于长达两周。 使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度，使用和处理的建议？ 请发送电子邮件至：service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话：
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到：027-84254680

    • 提供订购信息
  • 为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号（CAS No.或产品名称）
  • 2. 发货地址
  • 3. 联系方法 (联系人，电话）
  • 4. 开票抬头 (如果需要发票的客户）
  • 5. 发票地址（发货地址与发票地址不同）
    • 发货时间
    1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学，并且还在增涨
  • Universidad de Buenos Aires (Argentina)
  • Rio de Janeiro State University (Brazil)
  • Kazusa DNA Research Institute (Japan)
  • University of Dicle (Turkey)
  • Pennsylvania State University (USA)
  • Harvard University (USA)
  • Colorado State University (USA)
  • University of Parma (Italy)
  • Sanford Burnham Prebys Medical Discovery Institute (USA)
  • University of Queensland (Australia)
  • VIB Department of Plant Systems Biology, UGent (PSB) (Belgium)
  • Worcester Polytechnic Institute (USA)
  • The Institute of Cancer Research (United Kingdom)
  • Guangzhou Institutes of Biomedicine and Health (China)
  • More...
    • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • J Liq Chromatogr R T2018, 41(12):761-769
  • Phytomedicine2022, 104:154318
  • Molecules2022, 27(14),4462
  • BMC Complement Altern Med.2019, 19(1):367
  • Br J Pharmacol.2016, 173(2):396-410
  • J Nat Med.2020, 74(1):65-75
  • J Biochem Mol Toxicol.2020, 34(7):e22489.
  • Mol Biol Rep.2022, doi: 10.1007
  • Drug Des Devel Ther.2023, 17:2461-2479.
  • Sci Rep. 2017, 12953(7)
  • Vietnam Journal of Food Control2022, 5(3):pp.390-401.
  • Food and Fermentation Industries2019, 45(7):45-51
  • Korean J of Crop Science2019, 452-458
  • Appl. Sci. 2021, 11(8),3437.
  • Drug Test Anal.2018, 10(10):1579-1589
  • International. J. of Food Properties 2017, 20:S131-S140
  • United States Patent Application2020, 20200038363
  • J Integr Plant Biol.2023, 13564.
  • Nutrients.2019, 11(4):E936
  • J Ethnopharmacol.2020, 249:112396
  • Lab Chip.2018, 18(6):971-978
  • Int J Mol Sci.2022, 23(21):13406.
  • Pharmaceuticals (Basel). 2021, 14(10):986.
  • ...
    • 生物活性
    Description: Pramipexole dihydrochloride could be used to treat Parkinson disease.
    Targets: Dopamine Receptor
    In vivo:
    Archives of Neurology [01 Jan 2010, 67(1):27-32]
    Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.[Pubmed: 20065126]
    Treatment of Parkinson disease commonly includes levodopa and dopamine agonists; however, the interaction of these 2 drugs is poorly understood. To examine the effects of a dopamine agonist on the motor response to levodopa.
    METHODS AND RESULTS:
    Double-blind, randomized, placebo-controlled, crossover clinical trial. Ambulatory academic referral center. Patients Thirteen patients with idiopathic Parkinson disease taking levodopa and experiencing motor fluctuations and dyskinesia. Eligible individuals were randomly assigned to receive Pramipexole dihydrochloride or placebo for 4 weeks followed by a 2-hour intravenous levodopa infusion on consecutive days at 2 rates and with blinded assessments. They were then crossed over to the alternate oral therapy for 4 weeks followed by levodopa infusion and reassessment. Change in finger-tapping speed, measured using the area under the curve (AUC) for finger taps per minute across time; peak finger-tapping speed; duration of response; time to "ON" (defined as a 10% increase in finger-tapping speed above baseline); walking speed; and dyskinesia AUC. Pramipexole with levodopa infusion increased finger-tapping speed beyond the change in baseline by a mean (SE) of 170 (47.2) per minute x minutes (P = .006) and more than doubled the AUC for finger-tapping speed. Pramipexole increased peak finger-tapping speed by a mean (SE) of 18 (8.5) taps per minute (P = .02) and improved mean (SE) walking speed (15.9 [0.70] vs 18.9 [0.70] seconds, P = .004). Pramipexole prolonged duration of response after levodopa infusion and shortened time to ON. Pramipexole increased mean (SE) baseline dyskinesia scores (26.0 [5.85] vs 12.1 [5.85] points, P = .05) and peak dyskinesia scores with levodopa infusion.
    CONCLUSIONS:
    Pramipexole augmented the motor response to levodopa beyond a simple additive effect and increased the severity of levodopa-induced dyskinesia. When considering a combination of these therapies, an appropriate balance should be maintained regarding gain of motor function vs worsening of dyskinesia.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.518 mL 17.5901 mL 35.1803 mL 70.3606 mL 87.9507 mL
    5 mM 0.7036 mL 3.518 mL 7.0361 mL 14.0721 mL 17.5901 mL
    10 mM 0.3518 mL 1.759 mL 3.518 mL 7.0361 mL 8.7951 mL
    50 mM 0.0704 mL 0.3518 mL 0.7036 mL 1.4072 mL 1.759 mL
    100 mM 0.0352 mL 0.1759 mL 0.3518 mL 0.7036 mL 0.8795 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    2-环己基乙胺; 2-Cyclohexylethylamine CFN00069 4442-85-7 C8H17N = 127.23 5mg QQ客服：3257982914
    N-甲基环己烷乙胺; N-Methylcyclohexaneethaneamine CFN00070 62141-38-2 C9H19N = 141.29 5mg QQ客服：215959384
    3,3'-[Iminobis(methylene)]bis-2(3H)furanone; 3,3'-[Iminobis(methylene)]bis-2(3H)furanone CFN00082 96562-86-6 C10H15NO4 = 213.23 5mg QQ客服：3257982914
    Cassipourine; Cassipourine CFN00442 14051-10-6 C14H22N2S4 = 346.60 5mg QQ客服：215959384
    酒石酸伐仑克林; Varenicline tartrate CFN90008 375815-87-5 C13H13N3.C4H6O6 = 361.35 5mg QQ客服：1413575084
    盐酸帕洛诺司琼; Palonosetron hydrochloride CFN90009 135729-62-3 C19H25ClN2O = 332.87 20mg QQ客服：2056216494
    盐酸普拉克索; Pramipexole dihydrochloride CFN90019 104632-25-9 C10H19Cl2N3S = 284.25 5mg QQ客服：3257982914
    雷美替胺; Ramelteon CFN90021 166597-26-9 C13H21NO2 = 259.34 5mg QQ客服：2159513211
    凝血酸，氨甲环酸; Tranexamic acid CFN90569 1197-18-8 C8H15NO2 = 157.21 20mg QQ客服：215959384

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用，不用于诊断或治疗程序。

    联系方式


    电机：027-84237783
    传真：027-84254680
    在线QQ: 1413575084
    E-Mail：manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家，科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产。